Vanguard Global Advisers’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$104K Sell
43,754
-47,957
-52% -$124K ﹤0.01% 2754
2026
Q2
$248K Buy
91,711
+60,944
+198% +$113K ﹤0.01% 2415
2026
Q1
$36.9K Buy
+30,767
New +$37.5K ﹤0.01% 3135

Other funds holding FATE

Vanguard Global Advisers's FATE Position: Q3 2026 in Review

Vanguard Global Advisers reduced its Fate Therapeutics (FATE) stake by 52% in Q3 2026, selling an estimated $124K and leaving 43,754 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #2754.

Vanguard Global Advisers first reported a position in FATE in Q1 2026 and has held it in 3 quarters since. The position peaked at $248K in Q2 2026. 142 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Vanguard Global Advisers held 43,754 shares of Fate Therapeutics worth $104K as of Q3 2026.
  • Vanguard Global Advisers sold 47,957 Fate Therapeutics shares in Q3 2026, an estimated $124K.
  • Fate Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2754 holding.
  • Vanguard Global Advisers first reported a position in Fate Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Fate Therapeutics position peaked at $248K in Q2 2026.
  • 142 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.